Efficient Anti-Tumor Immunotherapy Using Tumor Epitope-Coated Biodegradable Nanoparticles Combined With Polyinosinic-Polycytidylic Acid and an Anti-PD1 Monoclonal Antibody
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Vaccination with tumor peptide epitopes associated with MHC class I molecules is an attractive approach directed at inducing tumor-specific CTLs. However, challenges remain in improving the therapeutic efficacy of peptide epitope vaccines, including the low immunogenicity of peptide epitopes and insufficient stimulation of innate immune components in vivo. To overcome this, we aimed to develop and test an innovative strategy that elicits potent CTL responses against tumor epitopes. The essential feature of this strategy is vaccination using tumor epitope-loaded nanoparticles (NPs) in combination with polyinosinic-polycytidylic acid (poly-IC) and anti-PD1 mAb. Carboxylated NPs were prepared using poly(lactic-co-glycolic acid) and poly(ethylene/maleic anhydride), covalently conjugated with anti-H-2Kb mAbs, and then attached to H-2Kb molecules isolated from the tumor mass (H-2b). Native peptides associated with the H-2Kb molecules of H-2Kb-attached NPs were exchanged with tumor peptide epitopes. Tumor peptide epitope-loaded NPs efficiently induced tumor-specific CTLs when used to immunize tumor-bearing mice as well as normal mice. This activity of the NPs significantly was increased when co-administered with poly-IC. Accordingly, the NPs exerted significant anti-tumor effects in mice implanted with EG7-OVA thymoma or B16-F10 melanoma, and the anti-tumor activity of the NPs was significantly increased when applied in combination with poly-IC. The most potent anti-tumor activity was observed when the NPs were co-administered with both poly-IC and anti-PD1 mAb. Immunization with tumor epitope-loaded NPs in combination with poly-IC and anti-PD1 mAb in tumor-bearing mice can be a powerful means to induce tumor-specific CTLs with therapeutic anti-tumor activity.
Abstract
Vaccination with tumor peptide epitopes associated with MHC class I molecules is an attractive approach directed at inducing tumor-specific CTLs. However, challenges remain in improving the therapeutic efficacy of peptide epitope vaccines, including the low immunogenicity of peptide epitopes and insufficient stimulation of innate immune components in vivo. To overcome this, we aimed to develop and test an innovative strategy that elicits potent CTL responses against tumor epitopes. The essential feature of this strategy is vaccination using tumor epitope-loaded nanoparticles (NPs) in combination with polyinosinic-polycytidylic acid (poly-IC) and anti-PD1 mAb. Carboxylated NPs were prepared using poly(lactic-co-glycolic acid) and poly(ethylene/maleic anhydride), covalently conjugated with anti-H-2Kb mAbs, and then attached to H-2Kb molecules isolated from the tumor mass (H-2b). Native peptides associated with the H-2Kb molecules of H-2Kb-attached NPs were exchanged with tumor peptide epitopes. Tumor peptide epitope-loaded NPs efficiently induced tumor-specific CTLs when used to immunize tumor-bearing mice as well as normal mice. This activity of the NPs significantly was increased when co-administered with poly-IC. Accordingly, the NPs exerted significant anti-tumor effects in mice implanted with EG7-OVA thymoma or B16-F10 melanoma, and the anti-tumor activity of the NPs was significantly increased when applied in combination with poly-IC. The most potent anti-tumor activity was observed when the NPs were co-administered with both poly-IC and anti-PD1 mAb. Immunization with tumor epitope-loaded NPs in combination with poly-IC and anti-PD1 mAb in tumor-bearing mice can be a powerful means to induce tumor-specific CTLs with therapeutic anti-tumor activity.
참고문헌 (47)
- Malonis RJ, "Peptide-based vaccines : current progress and future challenges", Chem Rev, 120, pp.3210~3229 (2020)
- Chen Q, "Novel survivin peptides screened with computer algorithm induce cytotoxic T lymphocytes with higher cytotoxic efficiency to cancer cells", Front Mol Biosci, 7, pp.570003~ (2020)
- Durgeau A, "Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy", Front Immunol, 9, pp.14~ (2018)
- Galloway SA, "Peptide super-agonist enhances T-cell responses to melanoma", Front Immunol, 10, pp.319~ (2019)
- Trac NT, "Peptide-based targeting of immunosuppressive cells in cancer", Bioact Mater, 5, pp.92~101 (2020)
- Hollingsworth RE, "Turning the corner on therapeutic cancer vaccines", NPJ Vaccines, 4, pp.7~ (2019)
- Feola S, "Uncovering the tumor antigen landscape: what to know about the discovery process", Cancers(Basel), 12, pp.1660~ (2020)
- Chen L, "Molecular mechanisms of T cell co-stimulation and co-inhibition", Nat Rev Immunol, 13, pp.227~242 (2013)
- Maimela NR, "Fates of CD8+ T cells in tumor microenvironment", Comput Struct Biotechnol J, 17, pp.1~13 (2018)
- Gutcher I, "APC-derived cytokines and T cell polarization in autoimmune inflammation", J Clin Invest, 117, pp.1119~1127 (2007)
- Pallerla S, "Cancer vaccines, treatment of the future : with emphasis on HER2-positive breast cancer", Int J Mol Sci, 22, pp.779~ (2021)
- Cho HI, "BiVax : a peptide", poly-IC subunit vaccine that mimics an acute infection elicits vast and effective anti-tumor CD8 T-cell responses, 2013, pp.62, 787~799
- Barrios K, "TriVax-HPV : an improved peptide-based therapeutic vaccination strategy against human papillomavirus-induced cancers", Cancer Immunol Immunother, 61, pp.1307~1317 (2012)
- SlingluffCL Jr, "The present and future of peptide vaccines for cancer : single or multiple, long or short, alone or in combination", Cancer J, 17, pp.343~350 (2011)
- Zhang L, "Peptide-based materials for cancer immunotherapy", Theranostics, 9, pp.7807~7825 (2019)
- Ma M, "Development of tumour peptide vaccines : From universalization to personalization", Scand J Immunol, 91, pp.e12875~ (2020)
- Abd-Aziz N, "Development of peptide-based vaccines for cancer", J Oncol, 2022, pp.9749363~ (2022)
- Heße C, "A tumor-peptide-based nanoparticle vaccine elicits efficient tumor growth control in antitumor immunotherapy", Mol Cancer Ther, 18, pp.1069~1080 (2019)
- Bouzid R, "Opportunities for conventional and in situ cancer vaccine strategies and combination with immunotherapy for gastrointestinal cancers, a review", Cancers(Basel), 12, pp.1121~ (2020)
- Nelde A, "The peptide vaccine of the future", Mol Cell Proteomics, 20, pp.100022~ (2021)
- Khong H, "Adjuvants for peptide-based cancer vaccines", J Immunother Cancer, 4, pp.56~ (2016)
- Oyewumi MO, "Nano-microparticles as immune adjuvants : correlating particle sizes and the resultant immune responses", Expert Rev Vaccines, 9, pp.1095~1107 (2010)
- He X, "Peptide delivery systems for cancer vaccines", Adv Ther, 1, pp.1800060~ (2018)
- Gibney GT, "Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma", Clin Cancer Res, 21, pp.712~720 (2015)
- Massarelli E, "Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer : a phase 2 clinical trial", JAMA Oncol, 5, pp.67~73 (2019)
- Hailemichael Y, "Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy", J Clin Invest, 128, pp.1338~1354 (2018)
- Barrueto L, "Resistance to checkpoint inhibition in cancer immunotherapy", Transl Oncol, 13, pp.100738~ (2020)
- Francis DM, "Blockade of immune checkpoints in lymph nodes through locoregional delivery augments cancer immunotherapy", Sci Transl Med, 12, pp.eaay3575~ (2020)
- 김상현, "Induction of Peptide-specific CTL Activity and Inhibition of Tumor Growth Following Immunization with Nanoparticles Coated with Tumor Peptide-MHC-I Complexes", Immune Network, 21(6), pp.1~15 (2021), 대한면역학회[DOI]
- Saini SK, "Dipeptides promote folding and peptide binding of MHC class I molecules", Proc Natl Acad Sci U S A, 110, pp.15383~15388 (2013)
- Jorgovanovic D, "Roles of IFN-γ in tumor progression and regression : a review", Biomark Res, 8, pp.49~ (2020)
- Bhat P, "Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity", Cell Death Dis, 8, pp.e2836~ (2017)
- Martins KA, "Vaccine adjuvant uses of poly-IC and derivatives", Expert Rev Vaccines, 14, pp.447~459 (2015)
- Liu W, "Peptide-based therapeutic cancer vaccine : Current trends in clinical application", Cell Prolif, 54, pp.e13025~ (2021)
- Bai S, "Aluminum nanoparticles deliver a dual-epitope peptide for enhanced anti-tumor immunotherapy", J Control Release, 344, pp.134~146 (2022)
- Carson CS, "A nanovaccine for enhancing cellular immunity via cytosolic co-delivery of antigen and polyIC RNA", J Control Release, 345, pp.354~370 (2022)
- Roy S, "Breakthrough concepts in immune-oncology : cancer vaccines at the bedside", J Leukoc Biol, 108, pp.1455~1489 (2020)
- Kumai T, "Antitumor peptide-based vaccine in the limelight", Vaccines(Basel), 10, pp.70~ (2022)
- Kim SH, "Induction of antigen-specific immune tolerance using biodegradable nanoparticles containing antigen and dexamethasone", Int J Nanomedicine, 14, pp.5229~5242 (2019)
- De Waele J, "A systematic review on poly(I : C)and poly-ICLC in glioblastoma : adjuvants coordinating the unlocking of immunotherapy", J Exp Clin Cancer Res, 40, pp.213~ (2021)
- Sultan H, "Poly-ICLC, a multi-functional immune modulator for treating cancer", Semin Immunol, 49, pp.101414~ (2020)
- Hargadon KM, "Immune checkpoint blockade therapy for cancer : an overview of FDA-approved immune checkpoint inhibitors", Int Immunopharmacol, 62, pp.29~39 (2018)
- Omar AI, "Enhanced oral bioavailability and biodistribution of atractylodin encapsulated in PLGA nanoparticle in cholangiocarcinoma", Clin Exp Pharmacol Physiol, 48, pp.318~328 (2021)
- Rezvantalab S, "PLGA-based nanoparticles in cancer treatment", Front Pharmacol, 9, pp.1260~ (2018)
- Roces CB, "Translating the fabrication of protein-loaded poly(lactic-co-glycolic acid)nanoparticles from bench to scale-independent production using microfluidics", Drug Deliv Transl Res, 10, pp.582~593 (2020)
- Baranov MV, "Modulation of immune responses by particle size and shape", Front Immunol, 11, pp.607945~ (2021)
- Sadat SM, "Effects of size and surface charge of polymeric nanoparticles on in vitro and in vivo applications", J Biomater Nanobiotechnol, 7, pp.91~108 (2016)